Cardiff Oncology, Inc. (CRDF) DCF Valuation

Cardiff Oncology, Inc. (CRDF) DCF Valuation

US | Healthcare | Biotechnology | NASDAQ
Cardiff Oncology, Inc. (CRDF) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Cardiff Oncology, Inc. (CRDF) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our (CRDF) DCF Calculator enables you to evaluate Cardiff Oncology, Inc. valuation using real-world financial data while offering complete flexibility to modify all essential parameters for improved forecasts.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .2 .4 .4 .4 .5 .6 .7 .9 1.0 1.2
Revenue Growth, % 0 49.38 -1.91 7.52 26.42 20.35 20.35 20.35 20.35 20.35
EBITDA -15.9 -18.8 -28.4 -39.7 -45.0 -.6 -.7 -.9 -1.0 -1.2
EBITDA, % -6497.93 -5147.4 -7911.98 -10276.17 -9224.18 -100 -100 -100 -100 -100
Depreciation .5 .5 .5 .2 .4 .5 .6 .7 .9 1.1
Depreciation, % 201.73 127.33 139.28 51.81 81.56 86.67 86.67 86.67 86.67 86.67
EBIT -16.4 -19.3 -28.9 -39.9 -45.4 -.6 -.7 -.9 -1.0 -1.2
EBIT, % -6699.66 -5274.73 -8051.25 -10327.98 -9305.74 -100 -100 -100 -100 -100
Total Cash 10.2 131.0 140.8 105.3 74.8 .6 .7 .9 1.0 1.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .2 .3 .5 .8 .3
Account Receivables, % 83.05 87.56 149.03 199.74 59.02
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0.000408163265 0 0 0 0 0.000081632653 0.000081632653 0.000081632653 0.000081632653 0.000081632653
Accounts Payable .7 1.4 1.4 2.0 2.0 .6 .7 .9 1.0 1.2
Accounts Payable, % 267.88 373.23 400.84 506.74 402.87 100 100 100 100 100
Capital Expenditure -.1 -.2 -.2 -.9 -.6 -.4 -.5 -.6 -.7 -.8
Capital Expenditure, % -27.76 -57.89 -57.1 -231.09 -119.26 -68.55 -68.55 -68.55 -68.55 -68.55
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -16.2 -19.3 -28.3 -38.6 -45.4 -.6 -.7 -.8 -1.0 -1.2
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -15.3 -18.4 -28.2 -39.0 -45.1 -2.1 -.6 -.7 -.8 -1.0
WACC, % 13.45 13.45 13.45 13.45 13.45 13.45 13.45 13.45 13.45 13.45
PV UFCF
SUM PV UFCF -3.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -1
Terminal Value -9
Present Terminal Value -5
Enterprise Value -8
Net Debt -20
Equity Value 11
Diluted Shares Outstanding, MM 45
Equity Value Per Share 0.25

What You Will Get

  • Comprehensive CRDF Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust parameters like WACC, tax rates, revenue growth, and capital expenditures.
  • Real-Time Calculations: Dynamic computation of intrinsic value and NPV.
  • Scenario Simulation: Analyze various scenarios to assess Cardiff Oncology's future performance.
  • User-Friendly Interface: Designed for professionals while remaining accessible to newcomers.

Key Features

  • Customizable Financial Inputs: Adjust essential parameters such as revenue projections, operating margins, and research & development expenses.
  • Instant DCF Valuation: Quickly computes intrinsic value, net present value (NPV), and additional financial metrics.
  • High-Precision Analysis: Leverages Cardiff Oncology’s (CRDF) actual financial data for accurate valuation results.
  • Effortless Scenario Testing: Easily evaluate different scenarios and analyze their impacts on financial outcomes.
  • Efficiency Booster: Streamlines the valuation process, removing the need to create intricate models from the ground up.

How It Works

  • Step 1: Download the prebuilt Excel template with Cardiff Oncology’s (CRDF) data included.
  • Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including Cardiff Oncology’s (CRDF) intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs.

Why Choose Cardiff Oncology, Inc. (CRDF)?

  • Innovative Solutions: Cutting-edge therapies designed to target cancer more effectively.
  • Proven Expertise: A team of seasoned professionals dedicated to advancing cancer treatment.
  • Robust Research: Backed by extensive clinical trials and scientific validation.
  • Patient-Centric Approach: Focused on improving patient outcomes and quality of life.
  • Commitment to Excellence: Striving for the highest standards in oncology care and research.

Who Should Use This Product?

  • Investors: Accurately assess Cardiff Oncology’s (CRDF) fair value prior to making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and strategic analysis related to Cardiff Oncology.
  • Consultants: Easily modify the template for valuation reports tailored to clients interested in Cardiff Oncology.
  • Entrepreneurs: Acquire knowledge about financial modeling practices employed by leading biotech firms.
  • Educators: Employ it as a teaching resource to illustrate valuation techniques in the biotech sector.

What the Template Contains

  • Preloaded CRDF Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.